Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Core Insights - Appili Therapeutics is actively seeking to expand its non-dilutive funding base through participation in the World Vaccine Congress Washington 2026, where executives will engage with global vaccine experts and government leaders [2][4]. Company Overview - Appili Therapeutics is a biopharmaceutical company focused on developing therapies for infectious diseases, with a mission to address life-threatening infections through a portfolio-driven approach [6]. - The company is advancing a diverse range of anti-infectives, including an FDA-approved metronidazole suspension, a vaccine candidate for biological threats, and a topical antiparasitic for disfiguring diseases [6]. Recent Collaborations and Funding - Appili has secured a US $40 million funding award from the National Institute of Allergy and Infectious Diseases to support the development of a fungal vaccine [8]. - The company is also advancing an in-licensed tularemia vaccine under a US $11.7 million award from the U.S. Air Force Academy [8]. - Additionally, Appili has launched LIKMEZ, a partnered liquid metronidazole product in the U.S., and is developing ATI-1801, a topical paromomycin product for leishmaniasis with demonstrated Phase 3 efficacy [8].